500 related articles for article (PubMed ID: 16219716)
1. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
Torlontano M; Crocetti U; Augello G; D'Aloiso L; Bonfitto N; Varraso A; Dicembrino F; Modoni S; Frusciante V; Di Giorgio A; Bruno R; Filetti S; Trischitta V
J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A
J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
[TBL] [Abstract][Full Text] [Related]
4. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
[TBL] [Abstract][Full Text] [Related]
5. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
6. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
7. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin.
Haugen BR; Ridgway EC; McLaughlin BA; McDermott MT
Thyroid; 2002 Jan; 12(1):37-43. PubMed ID: 11838729
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients.
Crocetti U; Durante C; Attard M; Maniglia A; Tumino S; Bruno R; Bonfitto N; Dicembrino F; Varraso A; Meringolo D; Filetti S; Trischitta V; Torlontano M
Thyroid; 2008 Oct; 18(10):1049-53. PubMed ID: 18816184
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
12. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
13. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.
Castagna MG; Brilli L; Pilli T; Montanaro A; Cipri C; Fioravanti C; Sestini F; Capezzone M; Pacini F
J Clin Endocrinol Metab; 2008 Jan; 93(1):76-81. PubMed ID: 17971424
[TBL] [Abstract][Full Text] [Related]
14. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
15. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
[TBL] [Abstract][Full Text] [Related]
16. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
17. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
18. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre.
Giovanni V; Arianna LG; Antonio C; Francesco F; Michele K; Giovanni S; Marco S; Giovanni L
Clin Endocrinol (Oxf); 2002 Feb; 56(2):247-52. PubMed ID: 11874417
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases.
Torlontano M; Attard M; Crocetti U; Tumino S; Bruno R; Costante G; D'Azzò G; Meringolo D; Ferretti E; Sacco R; Arturi F; Filetti S
J Clin Endocrinol Metab; 2004 Jul; 89(7):3402-7. PubMed ID: 15240622
[TBL] [Abstract][Full Text] [Related]
20. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]